10 patients, but one dropped out, so 9. 6 were given a negligible dose for safety and one of these later died. One of the three remaining lied about heart issues and had a serious heart attack immediately after injection. So at best you have a sample size of two. <i>Two people!!</i><p>Really not the promising study the title suggests.<p><i>"They plan to enroll ~40 more patients.<p>Meanwhile a new version of the therapy, VERVE-102, is in the works. The newcomer uses a similar base editing technology and an upgraded nanoparticle carrier with potentially better targeting.<p>The team plans to launch a randomized, placebo-controlled trial by 2025"</i><p>So that might be promising, albeit later.